Table 4 Performance of multi-modality RStumor, multi-modality RS1.0Â mm, clinical model and nomogram in the training, internal test and external test cohorts
Cohort | Model | AUC (95% CI) | ACC (%) | SEN (%) | SPE (%) | PPV (%) | NPV (%) |
|---|---|---|---|---|---|---|---|
Training cohort | Multimodality RStumor | 0.678 (0.625, 0.730) | 63.3 (247/390) | 73.9 (153/207) | 51.4 (94/183) | 63.2 (153/242) | 63.5 (94/148) |
| Â | Multimodality RS1.0Â mm | 0.862 (0.825, 0.899) | 80.0 (312/390) | 81.2 (168/207) | 78.7 (144/183) | 81.2 (168/207) | 78.7 (144/183) |
| Â | Clinical model | 0.750 (0.701, 0.798) | 70.5 (275/390) | 74.9 (155/207) | 65.6 (120/183) | 71.1 (155/218) | 69.8 (120/172) |
| Â | Nomogram | 0.883 (0.849, 0.918) | 80.8 (315/390) | 81.2 (168/207) | 80.3 (147/183) | 82.4 (168/204) | 79.0 (147/186) |
Internal test cohort | Multimodality RStumor | 0.682 (0.575, 0.789) | 67.0 (65/97) | 74.5 (38/51) | 58.7 (27/46) | 66.7 (38/57) | 67.5 (27/40) |
| Â | Multimodality RS1.0Â mm | 0.798 (0.708, 0.887) | 76.3 (74/97) | 68.6 (35/51) | 84.8 (39/46) | 83.3 (35/42) | 70.9 (39/55) |
| Â | Clinical model | 0.777 (0.686, 0.869) | 66.0 (64/97) | 68.6 (35/51) | 63.0 (29/46) | 67.3 (35/52) | 64.4 (29/45) |
| Â | Nomogram | 0.873 (0.799, 0.946) | 83.5 (81/97) | 86.3 (44/51) | 80.4 (37/46) | 83.0 (44/53) | 84.1 (37/44) |
External test cohort | Multimodality RStumor | 0.665 (0.583, 0.747) | 63.6 (110/173) | 33.8 (24/71) | 84.3 (86/102) | 60.0 (24/40) | 64.7 (86/133) |
| Â | Multimodality RS1.0Â mm | 0.789 (0.720, 0.857) | 72.8 (126/173) | 54.9 (39/71) | 85.3 (87/102) | 72.2 (39/54) | 73.1 (87/119) |
| Â | Clinical model | 0.781 (0.708, 0.854) | 73.4 (127/173) | 64.8 (46/71) | 79.4 (81/102) | 68.7 (46/67) | 76.4 (81/106) |
| Â | Nomogram | 0.841 (0.782, 0.900) | 77.5 (134/173) | 78.9 (56/71) | 76.5 (78/102) | 70.0 (56/80) | 83.9 (78/93) |